NCT00090090View on ClinicalTrials.gov

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

October 31, 2006

Conditions
Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
DRUG

Elsamitrucin

Trial Locations (7)

11021

North Shores University Hospital, Manhasset

90033

USC Norris Cancer Center, Los Angeles

90048

Tower Hematology Oncology Medical Group, Los Angeles

91343

North Valley Hematology Oncology Medical Group, Mission Hills

91505

Providence Saint Joseph Medical Center, Burbank

92270

Cancer and Blood Institute Medical Group, Rancho Mirage

94704

Alta Bates Cancer Center, Berkeley

All Listed Sponsors
lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT00090090 - Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter